Figure 3.
MRI Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer Stem Cells of a patient affected by left midbrain/thalamus, WHO grade 4, IDH wild-type, MGMT unmethylated gene, not operable, recurrent GBM.
A) Preoperative (stereotactic biopsy) MRI shows an intra-axial enhancing mass centered in the left midbrain/thalamus measuring 2.51 × 1.49 cm (12/22/2016).
B) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh stereotactic biopsy.
C) Control MRI (04/06/2017) following standard of care treatment with Temodar chemotherapy (75 mg/m2 daily) and radiation therapy (with radiation boost – 7 fractions) shows increased size of the left midbrain/thalamus lesion measuring 2.93 × 1.86 cm.
D) Failure of standard of care treatment prompted treatment with BCNU (150 mg/m2 every 6 weeks). Control MRI (11/08/2017) after 6 cycles of BCNU shows initial regression of the lesion measuring 1.53 × 0.95 cm.
E) Control MRI (02/20/2018) following Imatinib (400 mg daily) treatment shows regression of the lesion measuring 9.66 × 7.16 mm.
F) Control MRI (05/14/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion measuring 9.62 × 7.25 mm.
G) Control MRI (07/19/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion measuring 9.54 × 7.22 mm.
H) Control MRI (11/21/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion measuring 9.66 × 7.16 mm.